XML 77 R50.htm IDEA: XBRL DOCUMENT v3.6.0.2
(LOSS) EARNINGS PER SHARE (Tables)
 12 Months Ended
Dec. 31, 2016
Earnings Per Share [Abstract]  
Schedule of calculation of earnings per share
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc. for the years ended December 31, 2016, 2015 and 2014 were calculated as follows:
(in millions, except per share amounts)
 
2016
 
2015
 
2014
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.
 
$
(2,409
)
 
$
(292
)
 
$
881

Basic weighted-average number of common shares outstanding
 
347.3

 
342.7

 
335.4

Dilutive effect of stock options and RSUs
 
—

 
—

 
6.1

Diluted weighted-average number of common shares outstanding
 
347.3

 
342.7

 
341.5

 
 
 
 
 
 
 
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.
 
 
 
 
 
 
Basic
 
$
(6.94
)
 
$
(0.85
)
 
$
2.63

Diluted
 
$
(6.94
)
 
$
(0.85
)
 
$
2.58
Schedule of dilutive effect of stock options, RSUs and Convertible Notes on weighted-average number of common shares outstanding
The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
(in millions)
2016
 
2015
Basic weighted-average number of common shares outstanding
347.3

 
342.7

Dilutive effect of stock options and RSUs
2.8

 
6.1

Diluted weighted-average number of common shares outstanding
350.1

 
348.8